Understanding the detailed mechanism of action of glucagon-like peptide 1 receptor (GLP-1R) agonists on distinct topographic and genetically defined brain circuits is critical for improving the efficacy and mitigating adverse side effects of these compounds. In this mini-review, we propose that the central nucleus of the amygdala (CeA) is a critical mediator of GLP-1R agonist-driven hypophagia. Here, we review the extant literature demonstrating CeA activation via GLP-1R agonists across multiple species and through multiple routes of administration. The precise role of GLP-1Rs within the CeA is unclear but the site-specific GLP-1Rs may mediate distinct behavioral and physiological hallmarks of GLP-1R agonists on food intake. Thus, we propose important novel directions and methods to test the role of the CeA in mediating GLP-1R actions.
Data from two waves of the Social Environment and Biomarkers of Aging Study in Taiwan were analyzed to determine the effects of custodial grandparenting on health in a longitudinal sample. Self-reported measures on respondents’ perception of their health, six health biomarkers, the presence of twelve diseases, and a measure of stress were included. Custodial Grandparents (CGPs) were significantly more likely to report worse health than their peers. However, there were no significant differences in biomarkers, and CGPs were only significantly different from non-custodial grandparents (nCGPs) regarding lower respiratory disease. Results suggest that CGPs do not have significantly worse health than nCGPs, but report feeling less healthy. This disparity is suspected to be due to energy levels or stress sources not assessed by the variables in the original study. These results and their implications based upon the stress-coping model elucidate the need to design interventions that incorporate the East Asian cultural values and practices in order to promote better health outcomes for CGP populations overall.
Substantia nigra pars compacta dopamine neuron loss and Lewy pathology, aggregates of α-synuclein, characterize Parkinson’s disease and Dementia with Lewy Bodies. Lewy pathology localizes to cortical neurons, and is found as Lewy neurites in the striatum, but its effects on excitatory synaptic function are just beginning to be understood. Corticostriatal projections regulate motor and cognitive behaviors impaired in these disorders. Here, α-synuclein aggregation was induced in mouse M2 cortex, a vulnerable region in human disease. Early after initiation, aggregates localized to corticostriatal vesicular glutamate transporter 1 (vGLUT1)-positive terminals, with sparing of spiny projection neuron (SPN) soma, and dopamine terminals and neurons. Corticostriatal presynaptic aggregates significantly impaired glutamatergic transmission, without overt cortical neuron loss, and were associated with decreased synaptic density and volume. Thus, formation of presynaptic α-synuclein aggregates impairs corticostriatal function without degeneration of cortical neurons or striatal dopamine terminals, suggesting pathologic α-synuclein is sufficient for synaptic loss. Our findings also point to early synaptic dysfunction as a therapeutic target in Lewy body diseases.